← All investment trusts
Investment trust
BPCRBiopharma Credit PLC
Managed by Pharmakon AdvisorsPedro Gonzalez de Cosio, Martin Friedman, Pablo Legorreta
Latest factsheet
31 Aug 2017
vs asset value
12.4% premium
Dividend yield
7.00%
BioPharma Credit's objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry.
12.4% premium — the shares change hands for more than the value of what the trust owns. Unlike an open-ended fund, a trust’s shares are bought and sold on the stock exchange, so their price is whatever buyers and sellers agree — not the value of the portfolio behind them.Share price 1.12 · asset value per share 1 (USD)
Cumulative performance
| Period | Trust |
|---|---|
| 1M | +2.11% |
| 1M | +0.34% |
| 3M | +2.11% |
| 3M | +1.03% |
| YTD | +2.11% |
| YTD | +0.76% |
| Since launch | +11.50% |
| Since launch | +1.71% |
Key facts
- Stock market ticker
- BPCR
- ISIN
- GB00BDGKMY29
- Currency
- USD
- Launched
- 27 Mar 2017
- Market value of shares
- £849.5m
- Management fee
- 1.00%
- Performance fee
- 10.00%
- Dividends paid
- Semi_annual
Source factsheets
| Date | Published by the trust |
|---|---|
| 31 Aug 2017 | View original factsheet ↗ |
| 30 Jun 2017 | View original factsheet ↗ |
| 31 May 2017 | View original factsheet ↗ |
| 30 Apr 2017 | View original factsheet ↗ |